Marvel Biosciences Pursues Orphan Drug Designation for Rett Syndrome Treatment

Marvel Biosciences Corp ( (TSE:MRVL) ) just unveiled an announcement.

Marvel Biosciences Corp. announced its intention to file for Orphan Drug Designation with the U.S. FDA for MB-204 as a treatment for Rett Syndrome, following promising preclinical results. This designation could accelerate MB-204’s development and strengthen Marvel’s position in rare neurological therapies, offering potential benefits such as market exclusivity and expedited regulatory processes.

More about Marvel Biosciences Corp

Marvel Biosciences Corp., based in Calgary, is a pre-clinical stage pharmaceutical development biotechnology company. It focuses on developing MB-204, a novel fluorinated derivative of the anti-Parkinson’s drug Istradefylline, targeting neurological diseases such as autism, depression, Alzheimer’s Disease, and neurodevelopmental disorders like Rett Syndrome and Fragile X Syndrome.

YTD Price Performance: -3.33%

Average Trading Volume: 32,903

Technical Sentiment Consensus Rating: Sell

Current Market Cap: C$6.5M

See more data about MRVL stock on TipRanks’ Stock Analysis page.